3Aware Announces Formation of Scientific Advisory Board
INDIANAPOLIS, INDIANA / ACCESS Newswire / June 23, 2025 / 3Aware, a leading innovator in real-world evidence (RWE) solutions for the medical device industry, today announced the formation of its Scientific Advisory Board. The Board will advise on clinical, regulatory, and scientific strategy to support the company's work in RWE for medical devices.
The Board's inaugural members are Dr. Bassil Akra, Dr. Philippe Auclair, and Dr. Trevor Carden. Dr. Akra will serve as Chair of the Scientific Advisory Board.
Bassil Akra, PhD, is the CEO of AKRA TEAM GmbH, a medical device consulting firm he founded in 2021. He is a leading expert on European medical device regulations, having helped shape the implementation of the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR). Dr. Akra previously served as Vice President of Strategic Business Development at TÜV SÜD, where he guided regulatory compliance and clinical strategy for medical device approvals.
Philippe Auclair, PharmD, PhD, is Former Senior Director of Regulatory Strategy and Advocacy at Abbott. He has over 30 years of experience in the pharmaceutical and medical device industries, with a focus on global regulatory policy and post-market surveillance. Dr. Auclair chairs MedTech Europe's working groups on post-market surveillance and Notified Bodies, and he has been recognized as a Fellow of the Regulatory Affairs Professionals Society (RAPS) for his contributions to regulatory science.
Trevor Carden, PhD, is Director of Scientific Affairs at Teleflex, where he leads the scientific and technical strategies for clinical evidence generation across a diverse medical device portfolio. With a PhD in genetics, genomics, and bioinformatics, Dr. Carden focuses on regulatory compliance and optimizing clinical evaluation processes.
'We are thrilled to welcome such esteemed experts to our Scientific Advisory Board,' said Amelia Hufford, PhD, Senior Vice President of Clinical & Regulatory Science at 3Aware. 'Their combined expertise in clinical research and regulatory policy will help ensure our real-world evidence initiatives meet the highest standards of scientific rigor and compliance.'
'This board's formation underscores 3Aware's commitment to delivering best-in-class solutions,' said Kyle Howes, Vice President of Sales at 3Aware. 'By engaging these industry leaders, we ensure our RWE platform continues to deliver exceptional value and instill confidence in our clients.'
'I am honored to join 3Aware's Scientific Advisory Board,' said Dr. Bassil Akra. 'Real-world evidence is increasingly critical for advancing medical device innovation and patient safety. I look forward to working with the 3Aware team to maximize the impact of RWE for device manufacturers.'
Contact InformationPhil Stoltzfus VP of Marketing & Public Relations
SOURCE: 3Aware
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
an hour ago
- Fox News
White House office tells agencies to apply 'Gold Standard Science' to depoliticize research, restore trust
EXCLUSIVE: The White House Office of Science and Technology on Monday directed federal agencies to implement "gold standard science" principles to depoliticize science and restore public trust, Fox News Digital has learned. White House Office of Science and Technology Policy Director Michael Kratsios sent guidance to federal research agencies Monday morning, incorporating President Donald Trump's executive order on "Restoring Gold Standard Science." Fox News Digital exclusively obtained the guidance sent to federal agencies. President Trump, in May, signed an executive order to restore "Gold Standard Science" as the cornerstone of federal scientific research. "Gold Standard Science" is "reproducible, transparent and falsifiable," according to the order. It is also "subject to unbiased peer review; clear about errors and uncertainties; skeptical of assumptions; collaborative and interdisciplinary; accepting of negative results as positive outcomes; and free from conflicts of interest." The executive order reinstated "the scientific integrity policies" of the first Trump administration and "ensures that science is no longer manipulated or misused to justify political ends." "President Trump's Gold Standard Science EO will transform the conduct and management of federal science, from research design to public communication, in order to strengthen scientific inquiry, rebuild public trust, and ensure the U.S. continues to be the global leader in rigorous, evidence-based science," Kratsios told Fox News Digital. "But federal agencies are only one part of our nation's research ecosystem." Kratsios added, "American universities, scientific journals, industry and philanthropic leaders all have a crucial role in improving the overall quality of research, and we encourage this executive action to serve as a model for the entire scientific enterprise." Kratsios sent the memo to federal agencies Monday morning to provide guidance to federal departments and agencies on implementing gold standard science "in the conduct and management of all aspects of their scientific activities, from research design to public communication." "By adopting these standards, agencies will strengthen scientific inquiry, rebuild public trust, and ensure the United States continues as the global leader in rigorous, evidence-based science," the memo states. Kratsios said that "Gold Standard Science" represents a "commitment to the highest standards of scientific integrity, defined by nine core tenets: reproducible; transparent; communicative of error and uncertainty; collaborative and interdisciplinary; skeptical of its findings and assumptions; structured for falsifiability of hypotheses; subject to unbiased peer review; accepting of negative results as positive outcomes; and without conflicts of interest." "These tenets ensure that federally-supported research and research used in federal decision-making is transparent, rigorous, and impactful, enabling federal decisions to be informed by the most credible, reliable, and impartial scientific evidence available," Kratsios wrote in the guidance. But "Gold Standard Science" is not limited to science, Kratsios said, saying that it is critical for tackling complex challenges in energy innovation and national security as well. "In an age of rapid technological progress and heightened public scrutiny, federally-funded and federally-performed science, and its use in Federal decision-making, must be beyond reproach," he wrote. As for conducting science "without conflicts of interest," Kratsios said it is imperative to ensure that "research is designed, executed, reviewed, and reported free from financial, personal, or institutional influences that could bias outcomes or undermine objectivity." "This approach is important for generating trustworthy and credible new knowledge, as it upholds scientific integrity, fosters public confidence, and ensures that results reflect evidence rather than external agendas," the memo states. "Maintaining freedom from conflicts of interest requires researchers, reviewers, and managers to disclose all relevant affiliations, funding sources, and relationships relevant to the science conducted, adhering to stringent ethical standards supported by strong institutional oversight, transparent reporting systems, and independent expert review mechanisms." Kratsios said agencies must "prioritize conducting and managing scientific research free from conflicts of interest to advance unbiased science," and must "require disclosure of all relevant conflicts of interest by researchers, reviewers, and agency officials involved in the funding or performance of Federal research." "These efforts include requiring comprehensive, standardized disclosure of all financial, personal, or institutional interests in research proposals, publications, peer and merit reviews, and data repositories, with clear and standardized protocols to identify, mitigate, and manage potential biases," the memo states. "Agencies should mandate the use of independent oversight approaches and enforce strict conflict-of-interest policies." Agencies have 60 days to outline "Gold Standard Science" implementation plans, including plans for training and resources to ensure agency personnel understand the new policy, and the use of artificial intelligence-driven tools when practical. After Trump signed the May executive order to restore gold standard science, a senior White House official said there had been a decline in "disruptive research" and investments in biomedical research, along with "serious cases" of fraud and misconduct and the inability to reproduce scientific methods for the purpose of restoring public trust. The official also blamed policy responses to the COVID-19 pandemic and "woke DEI initiatives" for endangering the public's trust in government scientists. Now-retired National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci was repeatedly denounced for flip-flopping and obfuscating during his time engineering the federal response to COVID-19, leading many, particularly on the right, to disregard and dismiss the legitimacy of federal health authorities outright. That order cites the fact the Biden administration included political edits from teachers' unions in school-reopening guidance, instead of leading with any scientific evidence. Meanwhile, in an exclusive interview with Fox News Digital in April, Kratsios echoed Trump, saying the U.S. is in the "golden age" and that this special moment in time is "underpinned by unbelievable science and technology."
Bloomberg
an hour ago
- Bloomberg
Novo Exits Hims & Hers Partnership, Citing Compounding Concerns
Novo Nordisk A/S is terminating a recently formed obesity-drug partnership with Hims & Hers Health Inc. that had been touted as a way to boost sales in the US. The Danish drugmaker cited concerns about sales of compounded drugs and misleading marketing in a statement Monday. Hims & Hers shares plunged 18% in trading before US exchanges opened. Novo fell as much as 5% in Copenhagen.
Washington Post
an hour ago
- Washington Post
Health insurers promise to improve coverage reviews that prompt delays and complaints
The nation's major health insurers are promising to scale back and improve a widely despised practice that leads to care delays and complications. UnitedHealthcare, CVS Health's Aetna and dozens of other insurers said Monday that they plan to reduce the scope of health care claims subject to prior authorization, standardize the process and expand the number of responses done in real time.
